Sponsor content

Expanding the therapeutic index of ADCs

Synaffix’s site-specific–conjugation and payload-enhancement technologies are improving the safety and efficacy of antibody-drug conjugates (ADCs) without the need for antibody engineering. To download the full article, please sign in.

Go to the profile of Synaffix
Mar 01, 2016
Upvote 2 Comment
Page of
Go to the profile of Synaffix


Synaffix enables ADCs for oncology that are both safer and more effective as well as easier to manufacture.

No comments yet.